News

Caio Tojar analyzes regulatory advances in clinical research in Brazil and tax challenges in an article for ConJur

The modernization of the rules governing clinical research in Brazil represents an important step forward in attracting investment, developing new medicines and expanding patients’ access to innovative treatments. However, for the country to consolidate its competitiveness in this sector, regulatory progress must be accompanied by an appropriate tax environment.

In an article published by Revista Consultor Jurídico (ConJur), Caio Tojar analyses the changes introduced by Law No. 14,874/2024 and its implementing regulations, which have brought greater predictability to the approval procedures for clinical research in Brazil.

Among the main advances, the author highlights the establishment of deadlines for ethical and health regulatory reviews, as well as the simplification of procedures applicable to studies conducted across different institutions. These measures help reduce regulatory barriers and make Brazil more attractive for international research and development projects.

Read the full article.